Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure (2018)

  • Authors:
  • USP affiliated authors: MARANHAO, RAUL CAVALCANTE - FCF ; KALIL FILHO, ROBERTO - FM ; BARRETTO, ANTONIO CARLOS PEREIRA - FM
  • USP Schools: FCF; FM; FM
  • DOI: 10.1186/s12944-018-0888-0
  • Subjects: NANOPARTÍCULAS; INSUFICIÊNCIA CARDÍACA; LIPOPROTEÍNAS
  • Agências de fomento:
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1186/s12944-018-0888-0 (Fonte: oaDOI API)
    • Este periódico é de acesso aberto
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: gold
    • Licença: cc-by

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      MARTINELLI, Ana Elisa Marabini; MARANHÃO, Raul Cavalcante; CARVALHO, Priscila O; et al. Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure. Lipids in Health and Disease, London, v. 17, n. 1, p. 1-9, 2018. Disponível em: < http://dx.doi.org/10.1186/s12944-018-0888-0 > DOI: 10.1186/s12944-018-0888-0.
    • APA

      Martinelli, A. E. M., Maranhão, R. C., Carvalho, P. O., Freitas, F. R., Silva, B. M. O., Curiati, M. N. C., et al. (2018). Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure. Lipids in Health and Disease, 17( 1), 1-9. doi:10.1186/s12944-018-0888-0
    • NLM

      Martinelli AEM, Maranhão RC, Carvalho PO, Freitas FR, Silva BMO, Curiati MNC, Kalil Filho R, Barretto ACP. Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure [Internet]. Lipids in Health and Disease. 2018 ; 17( 1): 1-9.Available from: http://dx.doi.org/10.1186/s12944-018-0888-0
    • Vancouver

      Martinelli AEM, Maranhão RC, Carvalho PO, Freitas FR, Silva BMO, Curiati MNC, Kalil Filho R, Barretto ACP. Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure [Internet]. Lipids in Health and Disease. 2018 ; 17( 1): 1-9.Available from: http://dx.doi.org/10.1186/s12944-018-0888-0

    Referências citadas na obra
    Ponikowski P, Anker SD, Al Habib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1:4–25.
    Hamo CE, Gheorghiade M, Butler J. Novel endpoints for heart failure clinical trials. Curr Heart Fail Rep. 2017;14:210–6.
    Kim HN, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015–9.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391–479.
    Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464–70.
    Cai A, Li X, Zhong Q, Li M, Wang R, Liang Y, et al. Associations of high HDL cholesterol level with all-cause mortality in patients with heart failure complicating coronary heart disease. Medicine (Baltimore). 2016;95:e3974.
    Freitas HF, Barbosa EA, Rosa FH, Lima AC, Mansur AJ. Association of HDL cholesterol and triglycerides with mortality in patients with heart failure. Braz J Med Biol Res. 2009;42:420–5.
    Sposito AC, Vinagre CGC, Santos RD, Stolf N, Bocchi E, Ramires JAF, et al. Intravascular lipolysis of TG-rich particles is accelerated in patients with heart failure. Circulation. 2002;106:S572.
    Nakagomi A, Seino Y, Noma S, Kohashi K, Kosugi M, Kato K, et al. Relationships between the serum cholesterol levels, production of monocyte proinflammatory cytokines and long-term prognosis in patients with chronic heart failure. Intern Med. 2014;53:2415–24.
    Drayna D, Jarnagin AS, McLean J. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 1987;327:632–4.
    Barter PJ. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2029–31.
    Maranhão RC, Freitas FR. HDL metabolism and atheroprotection: predictive value of lipid transfers. Adv Clin Chem. 2014;65:1–41.
    Sprandel MC, Hueb WA, Segre A, Ramires JA, Kalil-Filho R, Maranhão RC. Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:107–15.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193–9.
    Maranhão RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Metabolic behavior in rats of a non protein microemulsion resembling low-density lipoprotein. Lipids. 1993;28:691–6.
    Lo Prete AC, Dina CH, Azevedo CH, Puk CG, Lopes NH, Hueb WA. In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. Lipids. 2009;44:917–94.
    Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations lipid concentrations to heart failure incidence: the Framingham heart study. Circulation. 2009;120:2345–51.
    Mehra MR, Uber PA, Lavie CJ, Milani RV, Park MH, Ventura HO. High-density lipoprotein cholesterol levels and prognosis in advanced heart failure. J Heart Lung Transplant. 2009;28:876–80.
    Iwaoka M, Obata J, Abe M, Nakamura T, Kitta Y, Kodama Y, et al. Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with non ischemic heart failure. J Card Fail. 2007;13:247–53.
    Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, et al. CORONA of fatal and non-fatal outcomes in the controlled Rosuvastatin multinational trial in heart failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009;11:281–91.
    Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. CETP inhibition, HDL raising and progression of coronary atherosclerosis: insights from ILLUSTRATE. Circulation. 2008;118:2506–14.
    Cazita PM, Barbeiro DF, Moretti AI, Quintão EC, Soriano FG. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock. 2008;30:590–5.
    Venancio TM, Machado RM, Castoldi A, Amano MT, Nunes VS, Quintao EC, et al. CETP lowers TLR4 expression which attenuates the inflammatory response induced by LPS and polymicrobial sepsis. Mediat Inflamm. 2016;2016:1784014.
    Kostner GM, Knipping G, Groener JE, Zechner R, Dieplinger H. The role of LCAT and cholesteryl ester transfer proteins for the HDL and LDL structure and metabolism. Adv Exp Med Biol. 1987;210:79–86.
    Husebye T, Eritsland J, Arnesen H, Bjørnerheim R, Mangschau A, Seljeflot I, et al. Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure. PLoS One. 2014;9:e112359.
    Nymo SH, Hulthe J, Ueland T, McMurray J, Wikstrand J, Askevold ET, et al. Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail. 2014;16:68–75.
    Jug B, Salobir BG, Vene N, Sebestjen M, Sabovic M, Keber I. Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessel. 2009;24:271–6.
    Vaz Pérez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, Anker SD, Rauchhaus M. The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 2010;141:39–43.